Catalyst Wire Dossier Catalyst Wire Dossier

Sacituzumab Tirumotecan (MK-2870)

sacituzumab tirumotecan · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Sacituzumab Tirumotecan (MK-2870), covering 2026-02-19 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) [Phase 3]

See pricing